Drug intelligence / Profile preview

captopril + furosemide

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Oral

Overview

Captopril + furosemide is a combination of an angiotensin-converting enzyme (ACE) inhibitor and a loop diuretic used to treat hypertension and heart failure. Captopril works by inhibiting the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and blood pressure. Furosemide acts on the kidneys by inhibiting sodium-potassium-chloride cotransporters in the ascending loop of Henle, increasing water and electrolyte excretion. The combination provides additive blood pressure lowering effects but requires careful monitoring due to increased risks of renal failure and hypotension.

Other names: captopril + frusemide

Targets

ACE (Angiotensin Converting Enzyme)NKCC2 (Sodium-potassium-chloride cotransporter 2)

Beyond the preview

Go deeper on captopril + furosemide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on captopril + furosemide.

Explore the full profile